Yahoo Web Search

  1. Company News For Sep 10, 2019

    Zacks via Yahoo FinanceSep 10 13:31 PM

    ul> AT&T Inc. rsquo;s T shares gained 1.5% after activist investor Paul Singer's Elliott Management revealed that it acquired a stake worth $3.2 billion in the telecom giant's stock. li> Alcoa Corp.

  2. An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage ...

  3. Horizon Therapeutics plc HZNP recently announced that the FDA has accepted the Biologics License Application (BLA) for its investigational medicine, teprotumumab, for the treatment of active ...

  4. Shares of Adaptimmune Therapeutics plc ADAP rose about 8% after the company announced that the FDA has granted Orphan Drug Designation (ODD) to SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program ...

  5. Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan

    Zacks via Yahoo FinanceSep 10 15:39 PM

    Alexion Pharmaceuticals, Inc. ALXN announced a license agreement with BridgeBio Pharma, Inc.’s BBIO subsidiary Eidos Therapeutics, Inc. EIDX. Per the terms of the deal, ...

  6. Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance

    Zacks via Yahoo FinanceSep 12 14:13 PM

    Puma Biotechnology, Inc. PBYI announced that the FDA has accepted for review its supplemental New Drug Application (sNDA) of Nerlynx (neratinib). The sNDA is seeking approval of Nerlynx ...

  7. We'll apply a basic P/E ratio analysis to Amgen Inc.'s (NASDAQ:AMGN), to help you decide if the stock is worth further research. Amgen has a P/E ratio of 15.38, based on ...

  8. International Association for the Study of Lung Cancer (IASLC) 2019 World Conference - Sept. in Barcelona, Spain 32nd European College of Neuropsychopharmacology (ECNP) Congress – Sept. in Copenhagen ...

  9. 5 Companies Hit 52-Week Highs

    GuruFocus.com via Yahoo FinanceSep 04 17:01 PM

    Amgen Inc. (NASDAQ:AMGN) reached the 52-week high of $208.62 Amgen Inc. is a leader in biotechnology-based human therapeutics, with historical expertise in renal ...

  10. The First Trust Capital Strength ETF (FTCS) was launched on 07/06/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Blend segment of the ...